Loading company…
Scitech Pharma uses AI to discover and develop small-molecule drugs.
Scitech Pharma develops small-molecule drug candidates for oncology, autoimmune diseases and central nervous system disorders. Its pipeline includes ST-1898, a Phase II candidate, and other candidates in Phase I; the company also develops drug design services using SigmaHIT® software. Founded in 2015, it is based in Beijing, China. In April 2024, it raised over CNY 100 million in a Series A+ round to advance clinical trials of ST-1898 and ST-1703.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in